article · Oxford Medical Case Reports
This case highlights the potential efficacy and tolerability of T-DXd in men and challenges the systematic exclusion of male patients from clinical trials involving HER2-low mBC. We advocate routine HER2-low testing and gender-inclusive trial design.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/omcr/omaf182
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
